Create your own free news widgets.

Cancer is on the decline in this country as new statistics today indicate. But the declines are concentrated among the cancers that receive the most research funding, while some of the fastest growing cancers are getting very little.

WASHINGTON (Reuters) - A study of Ethicon Endo-Surgery Inc's computerized system to help sedate patients undergoing a colonoscopy showed it was effective but other factors may have played a role, the U.S. Food and Drug Administration said in a memo released on Wednesday.

NEW YORK (AP) -- A Food and Drug Administration report released Wednesday recommends stronger warnings and dose limits on drugs containing the painkiller acetaminophen, citing an increased risk of liver injury....

The U.S. Food and Drug Administration (FDA) has decided to delay its approval of the wrinkle med Botox for the treatment of upper limb muscle spasticity in stroke victims.

Happy days are here again for the embryonic stem cell (ESC) research community, or at least they should be. The day after Barack Obama was inaugurated as president in January, the U.S. Food and Drug Administration green-lighted an application from Geron Corporation to pursue the first phase I clinical trial of an ESC-based therapy (in this case, for spinal cord injury).President Obama, who ran on a pro-ESC research platform, cannot take credit for that regulatory first, which was largely a coincidence of timing. But he has already made good on his promise to lift the burdensome restrictions on federally funded ESC studies imposed by his predecessor in 2001. Laboratories receiving federal money are once again free to work on the cell lines of their choice (with some important restrictions). [More]

Bristol-Myers Squibb Company (NYSE: BMY) announced that the U.S. Food and Drug Administration (FDA) has granted full approval for SPRYCEL® (dasatinib) for the treatment of adults in all phases of chronic myeloid leukemia (CML) (chronic, accelerated, or myeloid or lymphoid blast phase) with resistance or intolerance to prior therapy including Gleevec®* (imatinib mesylate).

Allergan, Inc. (NYSE:AGN) today announced it has received a complete response letter from the U.S. Food and Drug Administration (FDA) regarding the Company's Supplemental Biologics License Application (sBLA) for BOTOX® (Botulinum Toxin Type A) to treat upper limb spasticity in post-stroke adults. Allergan submitted its sBLA for this indication in the third quarter of 2008. The FDA has not requested additional pre-approval clinical studies.

Researchers have discovered that your stomach’s appetite signal, ghrelin, can also turn on gene signals that result in accumulation of stomach fat. The study means that rather than doing crunches to flatten your stomach spend more time getting your appetite under control and your stomach is likely to shrink. Ghrelin is required for normal health and a normal appetite. It is a hormone signal that is released in your stomach, in turn signaling your brain. It also signals the activation of growth hormone in your body, which is vital for overall rejuvenation and anti-aging. In other words, a normal appetite is required for good health. On the other hand, once leptin resistance sets in and excess weight is gained ghrelin signaling becomes compromised. It becomes excessive and loses it proper timing and rhythm. This leads to a routinely excess appetite signal, making you eat too much food. The new research shows that ghrelin also signals the fat c

Anaphylaxis Canada is responding to the growing public health challenge of keeping teens and young adults with potentially life-threatening food allergies safe by creating a number of interactive tools including a groundbreaking new website, http://www.whyriskit.ca, an online 'Reaction Registry' and radio podcasts.

In a historic shift in public health policy, Congress is poised to give the federal government sweeping new authority to regulate the manufacturing of cigarettes and other tobacco products. The legislation, long resisted by the tobacco industry, could allow consumers to see for the first time what chemicals and other additives tobacco companies put in their products. It would empower the Food and Drug Administration to put new limits on harmful ingredients and prohibit tobacco companies from marketing 'light' cigarettes. And it would give the FDA new authority to enlarge warning labels and severely restrict full-color advertising for cigarettes and other tobacco products. Yet the victory, which eluded anti-tobacco advocates for decades, comes with challenges as well as promise, as federal officials are given never-before-used tools to control a product that is still linked to some 400,000 deaths every year in the United States. Particularly tricky may be keeping up the momentum of